Stock search

Ticker or company name

EW card

EW price forecast

Edwards Lifesciences$107,11

P/E now is 60,5. Average over 5 years: 33,7 (range 29–44). The stock is 79% above its history.

Base · FY2030

$182,01+13,7% a year

The base case gives 13,7% a year, above your target of 10%.

Settings

%

No analyst consensus: assumptions come from the company's last 5 years. Change any in the table.

Assumptions by year

FY2026FY2027FY2028FY2029FY2030
Revenue growth, %
Net margin, %
Change in shares, %
Payout ratio, %
P/E low
P/E base
P/E high
Revenue$6,47 bn$6,91 bn$7,37 bn$7,87 bn$8,39 bn
Net income$2,26 bn$2,41 bn$2,57 bn$2,75 bn$2,93 bn
EPS$3,92$4,24$4,60$4,98$5,40

Changed values are highlighted. Bear and bull cases: growth ∓ 10,9%, margin ∓ 2 pp, low and high P/E.

Price at year end

  • Base
  • Bear – Bull
  • now $107,11

The dot is the base case, the line runs from bear to bull, the dashed line is today's price.

Result at the end of FY2030

Bear$85,60

Price change
−20,1%
A year
−5,3%
Fair value today
$57,80
Margin of safety
−46,0%

Base$182,01

Price change
+69,9%
A year
+13,7%
Fair value today
$122,91
Margin of safety
+14,7%

Bull$406,68

Price change
+279,7%
A year
+38,2%
Fair value today
$274,62
Margin of safety
+156,4%

What growth the price implies

For the stock to return 10% a year, revenue must grow 3,8% a year to FY2030 at a 34,9% margin and P/E 33,7.

Growth over 5 years
6,7%
Analyst consensus
no data
In your model
6,7%

Calculated from your assumptions. Not an investment recommendation.

Base · FY2030$182,01+13,7% a year